🔬 Our automated, high-throughput system excels in both target-based AND phenotypic screening approaches. MyoScreen™ truly shines in phenotypic discovery, where cellular responses directly reveal the most promising hits.
What sets MyoScreen™ apart in the screening landscape:
✓ Mature muscle models enabling access to novel targets and drugs
✓ Disease-relevant myoblasts (primary or immortalized cell lines available)
✓ Versatile custom-built assays and multiplexed readouts in 384-well plate format
✓ Standardized myotube morphology enhancing quantification of phenotypic differences
✓ Advanced capabilities including AI-powered image analysis to pick up subtle cell phenotypes
🍒 Cherry on the cake: assess potential toxic and cytostatic effects on myotubes during HIT ID.
💪 Behind MyoScreen™: CYTOO’s expert team of biologists and data scientists, specialized in muscle drug discovery across key disease areas including fat infiltration, inflammation, autophagy dysfunction, mitochondrial defects and muscle preservation.
Ready to accelerate your muscle drug discovery program? Contact us !
